ST Notch announced that the company received a notice from the US FDA and that the submitted application for a simple new drug for flunaviscline injection has been approved for marketing by the US FDA. The product specification is 250 mg/5 mL, and it has been approved for use in locally advanced or metastatic breast cancer with positive estrogen receptors after menopause. This product is the company's first formulation product approved in the US. It marks a landmark achievement for the company's pharmaceutical products going overseas and has a positive impact on increasing international sales of pharmaceutical products. Currently, this product has not been registered and declared domestically, no revenue has been generated, and there is uncertainty about production and sales.

ST Notch announced that the company received a notice from the US FDA and that the submitted application for a simple new drug for flunaviscline injection has been approved for marketing by the US FDA. The product specification is 250 mg/5 mL, and it has been approved for use in locally advanced or metastatic breast cancer with positive estrogen receptors after menopause. This product is the company's first formulation product approved in the US. It marks a landmark achievement for the company's pharmaceutical products going overseas and has a positive impact on increasing international sales of pharmaceutical products. Currently, this product has not been registered and declared domestically, no revenue has been generated, and there is uncertainty about production and sales.